Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Rapid Therapeutic Science Laboratories, Inc. (RTSL)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Mar-31-20 | Mar-31-19 | Mar-31-18 | Mar-31-17 | Mar-31-16 | Mar-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | -99.6% | | | | | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 4.3 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.1 | 0.0 | 0.0 | -4.3 | 0.0 | 0.0 | 0.0 |
| Gross margin | 62.5% | 85.2% | 21.7% | | | | | |
| Selling, general and administrative [+] | 2.1 | 2.0 | 0.4 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 |
| General and administrative | 2.1 | 2.0 | 0.4 | 0.2 | 0.1 | 0.0 | | 0.0 |
| Other operating expenses | -1.3 | -0.1 | -0.2 | -0.2 | -1.9 | | 0.0 | |
| EBITDA [+] | -0.8 | -1.9 | -0.2 | | -2.5 | | | |
| EBITDA growth | -57.6% | | -1635.1% | -100.4% | 11369.8% | | -100.0% | |
| EBITDA margin | -153324.7% | -1473.3% | -1821.0% | | | | | |
| Depreciation | 0.0 | -0.1 | 0.0 | | 0.0 | | | |
| EBITA | -0.8 | -1.9 | -0.2 | 0.0 | -2.5 | 0.0 | 0.0 | 0.0 |
| EBITA margin | -151141.4% | -1421.6% | -2231.3% | | | | | |
| Amortization of intangibles | 0.0 | 0.1 | 0.0 | | | | | |
| EBIT [+] | -0.8 | -1.9 | -0.2 | 0.0 | -2.5 | 0.0 | 0.0 | 0.0 |
| EBIT growth | -56.6% | | -2326.9% | -100.4% | 11445.6% | | -100.0% | |
| EBIT margin | -157463.3% | -1478.9% | -2641.7% | | | | | |
| Non-recurring items [+] | | | | | -2.4 | | | |
| Asset impairment | | | | | -2.4 | | | |
| Interest expense | 1.3 | 0.1 | 0.2 | 0.2 | 0.0 | | | |
| Interest expense | 1.3 | 0.1 | 0.2 | 0.2 | 0.0 | | | |
| Other income (expense), net | -0.7 | -0.1 | -0.2 | -0.2 | -2.4 | | | 0.0 |
| Pre-tax income | -2.9 | -2.1 | -0.6 | -0.3 | -2.6 | 0.0 | 0.0 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | |
| Net income | -2.9 | -2.1 | -0.6 | -0.3 | -2.6 | 0.0 | 0.0 | 0.0 |
| Net margin | -537056.7% | -1567.5% | -6834.3% | | | | | |
| |
| Basic EPS [+] | ($0.02) | ($0.01) | ($0.01) | ($0.29) | ($1.04) | ($0.01) | | |
| Growth | 23.6% | | -96.4% | -72.0% | 12878.4% | | | |
| Diluted EPS [+] | ($0.02) | ($0.01) | ($0.01) | ($0.29) | ($1.04) | ($0.01) | | |
| Growth | 23.6% | | -96.4% | -72.0% | 12878.4% | | | |
| |
| Shares outstanding (basic) [+] | 190.7 | 168.8 | 60.0 | 1.2 | 2.5 | 2.7 | | |
| Growth | 13.0% | | 4885.4% | -51.2% | -9.0% | | | |
| Shares outstanding (diluted) [+] | 190.7 | 168.8 | 60.0 | 1.2 | 2.5 | 2.7 | | |
| Growth | 13.0% | | 4885.4% | -51.2% | -9.0% | | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|